• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602587)   Today's Articles (2338)   Subscriber (49368)
For: Mestres JA, iMolins AB, Martínez LC, López-Muñiz JI, Gil EC, de Juan Ferré A, Del Barco Berrón S, Pérez YF, Mata JG, Palomo AG, Gregori JG, Pardo PG, Mañas JJ, Hernández AL, de Dueñas EM, Jáñez NM, Murillo SM, Bofill JS, Auñón PZ, Sanchez-Rovira P. Defining the optimal sequence for the systemic treatment of metastatic breast cancer. Clin Transl Oncol 2017;19:149-61. [PMID: 27314861 DOI: 10.1007/s12094-016-1520-2] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Accepted: 05/19/2016] [Indexed: 12/17/2022]
Number Cited by Other Article(s)
1
Jhaveri K, Marmé F. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Cancer Treat Rev 2024;123:102670. [PMID: 38211404 DOI: 10.1016/j.ctrv.2023.102670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 12/05/2023] [Accepted: 12/07/2023] [Indexed: 01/13/2024]
2
Al Mahmasani L, Amhaz G, Abou Zeidane R, Chamseddine N, Hatab T, Sabbagh S, Charafeddine M, Assi HI. Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer. Front Oncol 2023;13:1181375. [PMID: 37920158 PMCID: PMC10619648 DOI: 10.3389/fonc.2023.1181375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 10/03/2023] [Indexed: 11/04/2023]  Open
3
O'Rourke J, Warnick J, Doole J, De Keyser L, Drebert Z, Wan O, Thompson CN, London JW, Fairchild K, Palchuk MB. Exploring Breast Cancer Systemic Drug Therapy Patterns in Real-World Data. JCO Clin Cancer Inform 2023;7:e2300061. [PMID: 37851942 PMCID: PMC10642877 DOI: 10.1200/cci.23.00061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 07/06/2023] [Accepted: 07/07/2023] [Indexed: 10/20/2023]  Open
4
Alasmari MM. A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer. Cancers (Basel) 2022;15:cancers15010038. [PMID: 36612034 PMCID: PMC9817862 DOI: 10.3390/cancers15010038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Revised: 12/13/2022] [Accepted: 12/14/2022] [Indexed: 12/24/2022]  Open
5
Pouya FD, Rasmi Y, Gazouli M, Zografos E, Nemati M. MicroRNAs as therapeutic targets in breast cancer metastasis. Drug Deliv Transl Res 2022;12:1029-1046. [PMID: 33987801 DOI: 10.1007/s13346-021-00999-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/29/2021] [Indexed: 12/24/2022]
6
Fedele P, Ferro A, Sanna V, La Verde N, Paris I, Chiari R. Exploring metastatic breast cancer treatment changes during COVID-19 pandemic. J Chemother 2021;33:263-268. [PMID: 33047649 DOI: 10.1080/1120009x.2020.1829328] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Revised: 08/24/2020] [Accepted: 09/21/2020] [Indexed: 10/23/2022]
7
Vargas JE, Puga R, Lenz G, Trindade C, Filippi-Chiela E. Cellular Mechanisms Triggered by the Cotreatment of Resveratrol and Doxorubicin in Breast Cancer: A Translational In Vitro-In Silico Model. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2020;2020:5432651. [PMID: 33204396 PMCID: PMC7654215 DOI: 10.1155/2020/5432651] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 08/22/2020] [Accepted: 10/06/2020] [Indexed: 12/14/2022]
8
Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer. Molecules 2020;25:molecules25204606. [PMID: 33050377 PMCID: PMC7594023 DOI: 10.3390/molecules25204606] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 09/29/2020] [Accepted: 10/06/2020] [Indexed: 12/24/2022]  Open
9
Feinberg B, Hime S, Wojtynek J, Dokubo I, Gajra A, Smith Y, Kish J. Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment. Future Oncol 2020;16:2713-2722. [PMID: 32954797 DOI: 10.2217/fon-2020-0729] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]  Open
10
Nixon NA, Simmons C, Lemieux J, Verma S. Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership. Breast J 2020;26:488-493. [DOI: 10.1111/tbj.13525] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 07/06/2019] [Accepted: 07/08/2019] [Indexed: 01/05/2023]
11
Stangl S, Haas K, Eichner FA, Grau A, Selig U, Ludwig T, Fehm T, Stüber T, Rashid A, Kerscher A, Bargou R, Hermann S, Arndt V, Meyer M, Wildner M, Faller H, Schrauder MG, Weigel M, Schlembach U, Heuschmann PU, Wöckel A. Development and proof-of-concept of a multicenter, patient-centered cancer registry for breast cancer patients with metastatic disease-the "Breast cancer care for patients with metastatic disease" (BRE-4-MED) registry. Pilot Feasibility Stud 2020;6:11. [PMID: 32042437 PMCID: PMC7001276 DOI: 10.1186/s40814-019-0541-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 12/03/2019] [Indexed: 01/18/2023]  Open
12
Ma Y, Yan F, Wei W, Deng J, Li L, Liu L, Sun J. Litchi Seed Aqueous Extracts play a role in suppression of epithelial-mesenchymal transition, invasion and migration in breast cancer cells. Cell Cycle 2020;19:317-325. [PMID: 31918603 DOI: 10.1080/15384101.2019.1710912] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]  Open
13
Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer. Anticancer Drugs 2019;29:616-627. [PMID: 29782350 DOI: 10.1097/cad.0000000000000624] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
14
Sánchez-Rovira P, Zamora P, Salvador-Bofill J, Morales S, Martínez-Jáñez N, Martínez-de-Dueñas E, Lluch A, Illarramendi JJ, Gómez-Pardo P, Gavilá Gregori J, García-Palomo A, García-Mata J, Fernández Y, Del Barco S, de Juan A, Ciruelos E, Chacón JI, Calvo L, Barnadas A, Albanell J. Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologists. J Drug Assess 2019;8:62-69. [PMID: 31069129 PMCID: PMC6493326 DOI: 10.1080/21556660.2019.1604375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 03/26/2019] [Indexed: 11/24/2022]  Open
15
Abdel-Rahman O. M-bioscore: proposing a new statistical model for prognostic factors in metastatic breast cancer patients. J Comp Eff Res 2018;7:845-854. [PMID: 30192157 DOI: 10.2217/cer-2018-0006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]  Open
16
Ballinger TJ, Meier JB, Jansen VM. Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer. Front Oncol 2018;8:308. [PMID: 30148117 PMCID: PMC6095972 DOI: 10.3389/fonc.2018.00308] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2018] [Accepted: 07/20/2018] [Indexed: 12/26/2022]  Open
17
Bermejo de Las Heras B, Cortes Ramon Y Cajal J, Galve Calvo E, de la Haba Rodriguez J, Garcia Mata J, Moreno Anton F, Pelaez Fernandez I, Rodriguez-Lescure A, Rodriguez Sanchez CA, Ruiz-Borrego M, Remak E, Barra M, Rivero M, Soto Alvarez J. The economic burden of metastatic breast cancer in Spain. Eur J Hosp Pharm 2018;27:19-24. [PMID: 32064084 DOI: 10.1136/ejhpharm-2017-001453] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2018] [Revised: 06/15/2018] [Accepted: 06/26/2018] [Indexed: 01/05/2023]  Open
18
Petrossian K, Nguyen D, Lo C, Kanaya N, Somlo G, Cui YX, Huang CS, Chen S. Use of dual mTOR inhibitor MLN0128 against everolimus-resistant breast cancer. Breast Cancer Res Treat 2018;170:499-506. [PMID: 29623577 DOI: 10.1007/s10549-018-4779-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 03/31/2018] [Indexed: 12/14/2022]
19
Larionov AA. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Front Oncol 2018;8:89. [PMID: 29670855 PMCID: PMC5894159 DOI: 10.3389/fonc.2018.00089] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2017] [Accepted: 03/14/2018] [Indexed: 01/01/2023]  Open
20
Elserafi MM, Zeeneldin AA, Abdelsalam IM, Nassar HR, Moneer MM, Buhoush WH. First-line paclitaxel and cisplatin used sequentially or in combination in metastatic breast cancer: A phase II randomized study. J Egypt Natl Canc Inst 2018;30:13-20. [PMID: 29428373 DOI: 10.1016/j.jnci.2018.01.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 01/06/2018] [Accepted: 01/06/2018] [Indexed: 12/18/2022]  Open
21
Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to "seed and soil" hypothesis. Mol Cancer 2017;16:176. [PMID: 29197379 PMCID: PMC5712107 DOI: 10.1186/s12943-017-0742-4] [Citation(s) in RCA: 175] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Accepted: 11/07/2017] [Indexed: 02/07/2023]  Open
22
Miglietta F, Dieci M, Griguolo G, Guarneri V, Conte P. Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? Cancer Treat Rev 2017;60:100-108. [DOI: 10.1016/j.ctrv.2017.09.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Revised: 09/04/2017] [Accepted: 09/06/2017] [Indexed: 12/28/2022]
23
Brufsky AM. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treat Rev 2017;59:22-32. [PMID: 28719836 DOI: 10.1016/j.ctrv.2017.06.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Accepted: 06/21/2017] [Indexed: 12/21/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA